So what I gathered:
- No intent for a takeover from Doug's understanding and not something which RYD or TM typically do.
- There could be (but not guaranteed) further support from the US Government in bulk purchases of Febridx similar to what occurred with Covid to support the combating of antimicrobial resistance.
- Payments for the award (which is not repayable to BARDA) are based on milestones. These include establishing the test, initial patient in the test and completion of the test.
- The initial $3Million covers this. The remaining option will be to support expanding the CLIA waiver further to the under 12 age bracket, currently it is only available for 12-64 years of age.
More importantly:
This is the only test of its kind in the setting available. If I heard correctly, BARDA funding/budget was for $20Million specifically for Anti Microbial Resistance. Lumos has been granted nearly 50% of that funding.
- Forums
- ASX - By Stock
- Ann: Lumos and BARDA Partnership - Investor Presentation
LDX
lumos diagnostics holdings limited
Add to My Watchlist
7.41%
!
2.9¢

So what I gathered:- No intent for a takeover from Doug's...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.9¢ |
Change
0.002(7.41%) |
Mkt cap ! $21.70M |
Open | High | Low | Value | Volume |
2.8¢ | 2.9¢ | 2.8¢ | $44.36K | 1.538M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 104764 | 2.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.0¢ | 324100 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 104764 | 0.029 |
5 | 468600 | 0.028 |
3 | 218288 | 0.027 |
3 | 581461 | 0.026 |
7 | 641153 | 0.025 |
Price($) | Vol. | No. |
---|---|---|
0.030 | 324100 | 5 |
0.031 | 252105 | 5 |
0.032 | 51725 | 1 |
0.035 | 88000 | 1 |
0.037 | 493186 | 2 |
Last trade - 14.13pm 18/06/2025 (20 minute delay) ? |
Featured News
LDX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online